Prognostic value of PD‐L1 and PD ‐1 expression in upper tract urothelial carcinoma patients - Université de Reims Champagne-Ardenne Access content directly
Journal Articles BJU International Year : 2023

Prognostic value of PD‐L1 and PD ‐1 expression in upper tract urothelial carcinoma patients

Luca Campedel
  • Function : Author
Eva Compérat
  • Function : Author
Géraldine Cancel-Tassin
Justine Varinot
  • Function : Author
Christian Pfister
Clara Delcourt
  • Function : Author
Françoise Gobet
  • Function : Author
Mathieu Roumiguié
Pierre‐marie Patard
  • Function : Author
Gwendoline Daniel
  • Function : Author
Pierre Bigot
  • Function : Author
Julie Carrouget
Caroline Eymerit
  • Function : Author
Stéphane Larré
  • Function : Author
Priscilla Léon
Alain Ruffion
Myriam Decaussin-Petrucci
  • Function : Author
Thomas Bessède
  • Function : Author
Cédric Lebacle
Sophie Ferlicot
  • Function : Author
Grégoire Robert
  • Function : Author
Nam‐son Vuong
  • Function : Author
Magali Philip
  • Function : Author
Sébastien Crouzet
Xavier Matillon
Florence Mège-Lechevallier
  • Function : Author
Hervé Lang
  • Function : Author
Pascal Mouracade
  • Function : Author
Véronique Lindner
  • Function : Author
Paul Gougis
  • Function : Author
Olivier Cussenot
  • Function : Author
Morgan Rouprêt
  • Function : Author
Thomas Seisen
  • Function : Author

Abstract

Objective: To evaluate the prognostic value of PD-L1 and PD-1 expression in upper tract urothelial carcinoma (UTUC) patients.Materials and methods: A retrospective multicenter study was conducted in 283 UTUC patients treated with radical nephroureterectomy (RNU) between 2000 and 2015 at 10 French hospitals. Immunohistochemistry analyses were performed using 2 mm-core tissue micro-arrays with NAT105® and 28.8® antibodies at a 5% cut-off for positivity on tumor cells and tumor-infiltrating lymphocytes to evaluate PD-L1 and PD-1 expression, respectively. Multivariable Cox regression models were used to determine the independent predictors of recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS). Results: Overall, 63 (22.3%) and 220 (77.7%) UTUC patients had PD-L1 positive and negative disease, respectively, while 91 (32.2%) and 192 (67.8%) had PD-1 positive and negative disease, respectively. Patients who expressed PD-L1 or PD-1 were more likely to have ≥pT2(68.3% vs. 49.5%;p=0.009 and 69.2% vs. 46.4%;p<0.001, respectively) and high-grade(90.5% vs. 70.0%;p=0.001 and 91.2% vs. 66.7%; p<0.001, respectively) disease with lymphovascular invasion(52.4% vs. 17.3%;p<0.001 and 39.6% vs. 18.2%;p<0.001, respectively) as compared to those who did not. In multivariable Cox regression analysis adjusting for each other, PD-L1 and PD-1 expression were significantly associated with decreased RFS(HR=1.83;95%CI=[1.09-3.08];p=0.023 and HR=1.59; 95%CI=[1.00-2.54];p=0.049; respectively), CSS (HR=2.73; 95%CI=[1.48-5.04]; p=0.001 and HR=1.96; 95%CI=[1.12-3.45]; p=0.019; respectively) and OS (HR=2.08;95%CI=[1.23-3.53]; p=0.006 and HR=1.71; 95%CI=[1.05-2.78];p=0.031; respectively). In addition, multivariable Cox regression analyses evaluating the four-tier combination of PD-L1 and PD-1 expression showed that only [PD-L1 / PD-1 positive] patients(n=38; 13.4%) had significantly decreased RFS (HR=3.07; 95%CI=[1.70-5.52];p<0.001), CSS (HR=5.23; 95%CI=[2.62-10.43];p<0.001) and OS (HR=3.07; 95%CI=[1.70-5.52]; p<0.001) as compared to those with [PD-L1 / PD-1 negative] disease (n=167; 59.0%). Conclusions: We observed that PD-L1 and PD-1 expression were both associated with adverse pathological features that translated into an independent and cumulative adverse prognostic value in UTUC patients treated with RNU.
No file

Dates and versions

hal-04179609 , version 1 (10-08-2023)

Identifiers

Cite

Luca Campedel, Eva Compérat, Géraldine Cancel-Tassin, Justine Varinot, Christian Pfister, et al.. Prognostic value of PD‐L1 and PD ‐1 expression in upper tract urothelial carcinoma patients. BJU International, 2023, ⟨10.1111/bju.16129⟩. ⟨hal-04179609⟩

Collections

URCA P3CELL
12 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More